Cover Image
市場調查報告書

Brilinta(急性冠狀動脈症候群)- 預測與市場分析

Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 312377
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
Brilinta(急性冠狀動脈症候群)- 預測與市場分析 Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
出版日期: 2014年07月31日 內容資訊: 英文 59 Pages
簡介

急性冠狀動脈症候群(ACS)目前的市場,主要由抗血栓劑、抗高血壓劑、Statin所構成,由於標準治療已被充分確立,大多數皆為學名醫藥品。ACS市場由於伴隨了多數文明病(例如肥胖等)的高齡化人口、代謝異常(例如糖尿病等)得病率的增加,今後也預測將會成長。

本報告提供ACS治療藥物Brilinta調查分析,提供您疾病概要和治療指南,競爭情形,產品資訊,銷售額預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
    • 預後
    • QOL
  • 症狀

第4章 疾病的管理

  • 治療概要

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估

第6章 Brilinta(ticagrelor)

  • 概要
  • 功效
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表

目錄

GlobalData has released its new PharmaPoint Drug Evaluation report, "Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023". The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

Ticagrelor was approved for use in the EU in December 2010 (AstraZeneca, press release, December 6, 2010) under the brand name Brilique. In July 2011, the FDA approved ticagrelor for use in the US under the brand name Brilinta (AstraZeneca, press release, July 20, 2011). Brilinta is indicated for use in patients during the acute phase of ACS, along with standard aspirin therapy, at a loading dose of 180mg. During the chronic treatment phase, 90mg doses are taken twice daily with maintenance doses of aspirin not to exceed 100mg.

Scope

  • Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Aricept for the top seven countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for ACS
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Aricept performance
  • Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Treatment Overview

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Brilinta (ticagrelor)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety

6.4. SWOT Analysis

  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population
    • 7.4.2. Diagnosed Acute Coronary Syndrome Patients
    • 7.4.3. Percent Drug-Treated Patients
    • 7.4.4. General Pricing Assumptions
    • 7.4.5. Individual Drug Assumptions
    • 7.4.6. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Reviewer
    • 7.6.3. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Antiplatelet Agents that Inhibit Platelet Activation
  • Table 2: Anticoagulants that Inhibit the Coagulatory Cascade
  • Table 3: Symptoms of Acute Coronary Syndrome
  • Table 4: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI)
  • Table 5: Most Prescribed Drugs for ACS by Class in the Global Markets, 2014
  • Table 6: Leading Treatments for Acute Coronary Syndrome, 2014
  • Table 7: Product Profile - Brilinta (ticagrelor)
  • Table 8: Brilinta (ticagrelor) SWOT Analysis, 2014
  • Table 9: Global Sales Forecasts ($m) for Brilinta, 2013-2023
  • Table 10: Price Sources and Calculations, by Country
  • Table 11: Physicians Surveyed, By Country

List of Figures

  • Figure 1: The ACS Timeline and the Scope of GlobalData's ACS Report and Forecast
  • Figure 2: Progression of Coronary Artery Disease, Atherosclerotic Plaque Rupture, Thrombosis, and Acute Coronary Syndrome
  • Figure 3: Platelet and Coagulatory Factors Implicated in Thrombosis
  • Figure 4: Electrocardiography in the Diagnosis of ACS
Back to Top